Executive Summary: Precision Wins, Broad Bets Lose
September 2026 rewarded biomarker-selected and ultra-rare strategies and punished broad ones. The FDA delivered first-ever treatments for Alexander disease (Zanvastro) and Sanfilippo syndrome type A (Fayuvi), approved AbbVie's once-daily Juvmo for Parkinson's disease, and granted camizestrant (Etcamah) accelerated approval for ESR1-mutated breast cancer. Days later, however, the Phase 3 SERENA-4 trial of the same drug missed its primary endpoint in unselected first-line disease.
October is catalyst-dense: a hepatitis B functional-cure decision (bepirovirsen, Oct 26), a priority-review oncology ADC decision, and ESMO 2026 in Madrid (Oct 23–27).
Oncology: One Molecule, Two Verdicts
Camizestrant (Etcamah): Approved in SERENA-6 Setting, Misses in SERENA-4
On September 4, the FDA granted accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-mutated HR+/HER2- advanced breast cancer. About a week later AstraZeneca reported that SERENA-4 (camizestrant + palbociclib vs anastrozole + palbociclib, first line, no prior systemic therapy for advanced disease) showed a numerical PFS improvement but did not reach statistical significance. Hazard ratio, confidence interval and P-value were not disclosed, and no new safety concerns were reported.
Why the Two Trials Diverge
| Feature | SERENA-6 | SERENA-4 |
|---|---|---|
| Strategy | Switch AI to camizestrant on ctDNA-detected ESR1 mutation | Camizestrant from day one, unselected |
| Population | 315 patients on first-line AI + CDK4/6i | 1,371 patients, treatment-naïve for advanced disease |
| Primary PFS result | 16.0 vs 9.2 months; HR 0.44 (0.31–0.60) | Not significant (numerical benefit only) |
| Regulatory outcome | Accelerated approval (Sep 4) | No filing for broad first-line use |
- Testing is the product: value now depends on serial ESR1 ctDNA monitoring on first-line therapy; labs and diagnostics partners gain leverage.
- Oral SERD class read-through: competitors pursuing universal first-line replacement of the AI backbone face a higher evidentiary bar.
- Open question: full SERENA-4 data (subgroups, safety) are the key unknown; watch for presentation at a medical meeting.
Other Oncology Actions in September
- Sevabertinib (Hyrnuo, Bayer), Sep 9: accelerated approval for HER2-mutant non-squamous NSCLC.
- Lutetium Lu 177 vipivotide tetraxetan, Sep 1: approved with an androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer, moving radioligand therapy earlier in the disease.
- Iberdomide + daratumumab/hyaluronidase + dexamethasone: accelerated approval in multiple myeloma.
Rare Disease and Gene Therapy Firsts
Two Previously Untreatable Conditions Get a First Therapy
Approval Timeline: September 2026
Chart reflects the editor's tally of the actions profiled in this report, not an official FDA count.
Evidence and Risk Notes
- Fayuvi evidence base: 17 treated patients compared with 27 untreated natural-history controls. The label carries a thrombotic microangiopathy warning and a theoretical long-term AAV integration risk.
- Priority review voucher: Ultragenyx received one with the approval, a monetizable asset that supports further ultra-rare investment.
- Juvmo launch: pricing was not disclosed at approval; analysts expect gradual uptake while Medicare coverage is negotiated.
Pipeline Pulse: October 2026
Decision Countdown and Scenario Explorer
Time until bepirovirsen PDUFA (Oct 26, 2026)
GSK's bepirovirsen, an antisense oligonucleotide licensed from Ionis, is under priority review with Breakthrough Therapy designation for adults with chronic hepatitis B, based on the Phase 3 B-Well 1 and 2 trials. It would be the first approved functional-cure-directed therapy. Select a scenario:
Approval Scenario
- Class signal: validates ASO and siRNA approaches to HBsAg loss; GSK's sequential regimen with daplusiran/tomligisiran gains credibility.
- Partners: Ionis stands to benefit through its licensing arrangement with GSK.
- Payers: finite-duration therapy versus lifelong nucleos(t)ide analogues drives the pricing debate.